Genomic Testing Cooperative Information

Cancer is complex. A partial molecular picture can limit what clinicians know about a patient’s disease. Genomic Testing Cooperative analyzes both DNA and RNA to provide more comprehensive insight into cancer biology, supporting diagnosis, prognosis, monitoring, and precision medicine. Through advanced NGS, AI-enabled interpretation, RNA innovation, and a cooperative model for hospitals and laboratories, GTC is helping move cancer diagnostics toward a more complete, molecular-first future. Why GTC? Comprehensive DNA and RNA Testing GTC analyzes both DNA and RNA to provide broader molecular insight than limited or DNA-only approaches. More Complete Biomarker Insight GTC’s testing is designed to identify clinically relevant biomarkers that may help inform diagnosis, prognosis, monitoring, and precision medicine.